Effects of extracorporeal shockwave versus control group on pain and disability of chronic low back pain

Effects of extracorporeal shockwave versus control group on pain and disability of chronic low back pain: a randomized clinical trial

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20120215009014N508

Enrollment

Registered

2024-05-01

Start date

2024-05-21

Completion date

Unknown

Last updated

2024-05-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Low back pain. Low back pain

Interventions

Intervention 1: Intervention group: Tizanidine tablets, 1 mg for the first 2 nights, then 2 mg for 10 days, and Meloxicam tablets, 15 mg daily for 2 weeks, in addition to extracorporeal shock wave usi

Eligibility

Sex/Gender

All

Age

18 Years to 70 Years

Inclusion criteria

Inclusion criteria: Age 18 to 70 years Chronic lower back pain for more than 12 weeks

Exclusion criteria

Exclusion criteria: Pregnancy History of back surgery Mental and cognitive illness Fracture or tumor or infection of the lumbar vertebrae Coagulation disorders

Design outcomes

Primary

Measure	Time frame
The mean score of pain. Timepoint: Before the intervention and one and three months later. Method of measurement: Using Visual Analog Scale (VAS).;The mean score of disability. Timepoint: Before the intervention and one and three months later. Method of measurement: Using Oswestry questionnaire.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMobin Alvandi

Hamedan University of Medical Sciences

mobinalvand@yahoo.com+98 81 3838 0572

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026